SciTechnol
Clinical Dermatology Research Journal
ISSN: 2576-1439
2020
Vol.5 No.4

Treatment of resistant melasma, responsive to fractionated CO2 laser (2.940 nm) + drug delivery. 6 years follow up

Denise Rocha Luna Barcelos
CD Clinica Dermatologica, Brazil

Abstract

Objective: To determine the effect of ablative fractional photothermolysis on resistant melasma.

Methods: 64 patients (Fitzpatrick skin type 1 to 5) with resistant melasma were select. One session, of 2940nm ablative fractional Co2 laser were performed, and follow up the one session a year to maintenance. No other treatment was performed in the previous or subsequent months. The energy used ranged was very low from 5 mJ with 5% total coverage. Responses were evaluated by the researcher and the patients.

Results: 58 patients completed the study, out due side effects. In the opinion of the examining physicians, 52 patients the improvement at one month ranged from and for patients from 90% to 100%. Six patients achieved improvement of 75% 90% one month after the session. For patients the improvement at one month ranged. Previous impressions were maintained after years, with a annual session protocol, for the examining physician and the patients.

Conclusions: Efficient protocol with fractionated laser and drug delivery to resistant melasma with long term follow-up.

Biography:

Denise Barcelos is a dermatologist graduated 25 years ago, laser specialist, member of the Brazilian Society of Dermatology, Brazilian Society of Dermatologic Surgery, and Brazilian Laser Society in Medicine and Surgery. Author of the book "A look at beauty".

21st World Dermatology Congress; Tokyo, Japan - June 22-23, 2020.

Abstract Citation:

Denise Rocha Luna Barcelos, Treatment of resistant melasma, responsive to fractionated CO2 laser (2.940 nm) + drug delivery. 6 years follow up, World Dermatology 2020, 21st World Dermatology Congress; Tokyo, Japan – June 22-23, 2020 (https://worlddermatology.conferenceseries.com/abstract/2020/treatment-of-resistant-melasma-responsive-to-fractionated-co2-laser-2-940-nm-drug-delivery-6-years-follow-up)